Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
April 26 2022 - 3:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
April 26, 2022
(Commission File No. 001-40505)
Ambrx Biopharma Inc.
(Translation of registrants name into English)
Cayman
Islands
(Jurisdiction of incorporation or organization)
10975 Torrey Pines Road
La Jolla, California 92037, United States
(Address of registrants principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Earnings Release
On April 26, 2022, Ambrx Biopharma Inc. issued a press release regarding its financial results as of and for the full year ended December 31, 2021
and recent business highlights, which is attached to this Form 6-K as Exhibit 99.1.
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereto duly authorized.
|
|
|
Ambrx Biopharma Inc. |
|
|
By: |
|
/s/ Feng Tian |
Name: |
|
Feng Tian, Ph.D. |
Title: |
|
Chief Executive Officer |
Date: April 26, 2022
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
From Sep 2023 to Sep 2024